.Attribute Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ advanced breast cancer cells and also energetic or even steady mind metastases revealed regular intracranial activity and wide spread effectiveness of T-DXd.